CDDP, doxorubicin, and 5‐FU are the most commonly used chemotherapeutic drugs in TACE treatment for HCC.[21] Herein, we demonstrated that the MCB1‐overexpressing HCC cells were resistant to CDDP, and MCB1/p53 axis determines the CDDP response. The gene discussed is TP53; the disease is hepatocellular carcinoma.